Gossamer Bio
NEWS
Numerous biotech companies had filed for initial public offerings (IPOs) during the five-week government shutdown, but were unlikely to actually be able to be listed until the U.S. Securities and Exchange Commission (SEC) had a chance to review their filings.
San Diego-based Gossamer Bio is pulling the trigger on an initial public offering by harnessing a legal loophole that will allow the company to move forward with its listing plans despite the partial government shutdown, now in its 34th day.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
Gossamer Bio, headquartered in San Diego, announced plans for its initial public offering (IPO) just before Christmas.
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
JOBS
IN THE PRESS